MAPK3 and B-cell chronic lymphocytic leukemia: In vitro studies analyzing responses to BCR triggering have identified a subset of CLL patients exhibiting indolent disease with CLL cells containing anergic features (67), including a lack of BCR signaling capacity and constitutive activation of ERK1/2 (64).